Publicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (9)

2023

  1. Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation

    ESMO Open, Vol. 8, Núm. 4

  2. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

2021

  1. The transcription factor SLUG uncouples pancreatic cancer progression from the RAF–MEK1/2–ERK1/2 pathway

    Cancer Research, Vol. 81, Núm. 14, pp. 3849-3861

2017

  1. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2015

  1. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types

    Journal of the National Cancer Institute, Vol. 107, Núm. 12

  2. Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape

    Cell Reports, Vol. 12, Núm. 8, pp. 1300-1313

2014

  1. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33

    Human Molecular Genetics, Vol. 23, Núm. 24, pp. 6616-6633

2013

  1. EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

    Cancer Cell, Vol. 23, Núm. 5, pp. 677-692

2010

  1. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models

    Journal of Clinical Investigation, Vol. 120, Núm. 11, pp. 3940-3952